Press Releases

Press Releases

Aug 4, 2011
PISCATAWAY, NJ -- (MARKET WIRE) -- 08/04/11 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the second quarter of 2011.
May 31, 2011
PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Ana I. Stancic has been named Senior Vice President and Chief Financial Officer of the Company, effective June 8, 2011 . Ms.
May 19, 2011
PEG-SN38 Clinical Programs Continue in Metastatic Breast Cancer, Other Solid Tumors PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc.
May 6, 2011
--Investments in R&D translating to continued progress with oncology pipeline-- PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for the first quarter of 2011.
Apr 5, 2011
Third-Generation mRNA Antagonists Continue Showing Promise in Expanding Range of Oncology Indications Locked Nucleic Acid Technology to be Featured in RNA-Targeting Therapeutics Symposium PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc.
Mar 17, 2011
PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Richard C. Mulligan , Ph.D., has been appointed Vice-Chairman of the Board of Directors, effective immediately. Dr.
Feb 17, 2011
Pipeline Development Continues to Advance as Transformation to a Biotechnology Company is Complete PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its fourth-quarter and full-year 2010 financial results.
Feb 10, 2011
PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it will report its financial results for the quarter ended December 31, 2010 , on Thursday, February 17, 2011 at 4:00 pm Eastern Time (ET).
Jan 10, 2011
BRIDGEWATER, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration ( FDA ) and plan to commence enrollment into a Phase 1a/ 1b study shortly.
Dec 21, 2010
BRIDGEWATER, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the Company's Board of Directors has authorized the purchase of up to $200 million of outstanding shares of the Company's common stock.